Boston Scientific CorporationBSXNYSE
LOADING
|||
EBITDA Over Time
Trending higher, above historical average, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$3.94B
↑ 75% above average
Average (9y)
$2.25B
Historical baseline
Range
High:$3.94B
Low:$360.00M
CAGR
+30.4%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $3.94B | +14.0% |
| 2023 | $3.45B | +26.0% |
| 2022 | $2.74B | +8.9% |
| 2021 | $2.52B | +66.6% |
| 2020 | $1.51B | -31.6% |
| 2019 | $2.21B | -14.5% |
| 2018 | $2.58B | +28.8% |
| 2017 | $2.01B | +63.7% |
| 2016 | $1.23B | +240.6% |
| 2015 | $360.00M | - |